Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5881-5887

  Kobayashi, Tomoko ^a   Koizumi, Yoshiki ^b   Takeuchi, Junko S ^a   Misawa, Naoko ^a   Kimura, Yuichi ^a   Morita, Satoru ^c   Aihara, Kazuyuki ^d,e   Koyanagi, Yoshio ^a   Iwami, Shingo ^f   Sato, Kei ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c SHIZUOKA UNIVERSITY   (Japan)

^d INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMIT OF QUANTITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CELL LINE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, THEORETICAL; VIRUS REPLICATION;

EID: 84899085875     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00062-14     Document Type: Article

References (54)

1. Freed EO, Martin MA. 2007. HIVs and their replication, p 2107-2185. In Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Malim MH, Bieniasz PD. 2012. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2:a006940. http://dx.doi.org/10.1101/cshperspect.a006940.
3. Liddament MT, Brown WL, Schumacher AJ, Harris RS. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385-1391. http://dx.doi.org/10.1016/j.cub.2004.06.050.
4. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. 2004. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451-2458. http://dx.doi.org/10.1038/sj.emboj.7600246.
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. http://dx.doi.org/10.1038/nature00939.
6. Izumi T, Shirakawa K, Takaori-Kondo A. 2008. Cytidine deaminases as a weaponagainst retrovirusesandanewtarget for antiviral therapy.MiniRev.Med. Chem. 8:231-238. http://dx.doi.org/10.2174/138955708783744047.
7. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 4:868-877. http://dx.doi.org/10.1038/nri1489.
8. + T lymphocytes. J. Virol. 66: 6489-6495.
9. von Schwedler U, Song J, Aiken C, Trono D. 1993. Vif is crucial for human immunodeficiency virus type 1 proviralDNAsynthesis in infected cells. J. Virol. 67:4945-4955.
10. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV. 2013. HIV restriction by APOBEC3 in humanized mice. PLoS Pathog. 9:e1003242. http://dx.doi.org/10.1371/journal.ppat.1003242.
11. Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, Ohmichi M, Ito M, Takaori-Kondo A, Koyanagi Y. 2010. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J. Virol. 84:9546-9556. http://dx.doi.org/10.1128/JVI.00823-10.
12. Fitzgibbon JE, Mazar S, Dubin DT. 1993. A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res. Hum. Retroviruses 9:833-838. http://dx.doi.org/10.1089/aid.1993.9.833.
13. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. 2008. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 82:3125- 3130. http://dx.doi.org/10.1128/JVI.01533-07.
14. + T cells. J. Virol. 75:7973-7986. http://dx.doi.org/10.1128/JVI.75.17.7973-7986.2001.
15. + T cells in vivo. J. Virol. 79:1975-1980. http://dx.doi.org/10.1128/JVI.79.3.1975-1980.2005.
16. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA. 2008. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82:8172-8182. http://dx.doi.org/10.1128/JVI.01115-08.
17. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication- competent and -defective viral genomes. J. Virol. 65:3973-3985.
18. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. 2006. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80:9259-9269. http://dx.doi.org/10.1128/JVI.00888-06.
19. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. 2009. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J. Virol. 83:7805-7814. http://dx.doi.org/10.1128/JVI.00280-09.
20. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ. 2008. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res. Hum. Retroviruses 24:1285-1290. http://dx.doi.org/10.1089/aid.2008.0072.
21. Vartanian JP, Henry M, Wain-Hobson S. 2002. Sustained G→A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau groupOgenome. J. Gen. Virol. 83:801-805.
22. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. 1991. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65:1779-1788.
23. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A, Shaw GM, Hahn BH, Korber B, Seoighe C. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 5:e1000414. http://dx.doi.org/10.1371/journal.ppat.1000414.
24. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80:8450-8458. http://dx.doi.org/10.1128/JVI.00839-06.
25. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4:e1000231. http://dx.doi.org/10.1371/journal.ppat.1000231.
26. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282:2587-2595. http://dx.doi.org/10.1074/jbc.M607298200.
27. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. http://dx.doi.org/10.1128/AAC.46.6.1896-1905.2002.
28. Chiu YL, Greene WC. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353. http://dx.doi.org/10.1146/annurev.immunol.26.021607.090350.
29. Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS. 2008. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82:2652-2660. http://dx.doi.org/10.1128/JVI.02391-07.
30. Bohn MF, Shandilya SM, Albin JS, Kouno T, Anderson BD, McDougle RM, Carpenter MA, Rathore A, Evans L, Davis AN, Zhang J, Lu Y, Somasundaran M, Matsuo H, Harris RS, Schiffer CA. 2013. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21:1042-1050. http://dx.doi.org/10.1016/j.str.2013.04.010.
31. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K, Harris RS, Matsuo H. 2008. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452:116-119. http://dx.doi.org/10.1038/nature06638.
32. Izumi T, Io K, Matsui M, Shirakawa K, Shinohara M, Nagai Y, Kawahara M, Kobayashi M, Kondoh H, Misawa N, Koyanagi Y, Uchiyama T, Takaori-Kondo A. 2010. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc. Natl. Acad. Sci. U. S. A. 107:20798-20803. http://dx.doi.org/10.1073/pnas.1008076107.
33. Sato K, Misawa N, Fukuhara M, Iwami S, An DS, Ito M, Koyanagi Y. 2012. Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J. Virol. 86:5000-5013. http://dx.doi.org/10.1128/JVI.07062-11.
34. Kobayashi T, Ode H, Yoshida T, Sato K, Gee P, Yamamoto SP, Ebina H, Strebel K, Sato H, Koyanagi Y. 2011. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J. Virol. 85:932-945. http://dx.doi.org/10.1128/JVI.01668-10.
35. Sato K, Yamamoto SP, Misawa N, Yoshida T, Miyazawa T, Koyanagi Y. 2009. Comparative study on the effect of human BST-2/tetherin on HIV-1 release in cells of various species. Retrovirology 6:53. http://dx.doi.org/10.1186/1742-4690-6-53.
36. Sato K, Aoki J, Misawa N, Daikoku E, Sano K, Tanaka Y, Koyanagi Y. 2008. Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. J. Virol. 82:1021-1033. http://dx.doi.org/10.1128/JVI.01044-07.
37. Rose PP, Korber BT. 2000. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 16:400-401. http://dx.doi.org/10.1093/bioinformatics/16.4.400.
38. + T cells and macrophages. J. Virol. 87:444-453. http://dx.doi.org/10.1128/JVI.00676-12.
39. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85:11220-11234. http://dx.doi.org/10.1128/JVI.05238-11.
40. Zennou V, Bieniasz PD. 2006. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349:31- 40. http://dx.doi.org/10.1016/j.virol.2005.12.035.
41. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. 2006. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2:458-466. http://dx.doi.org/10.1038/nchembio817.
42. Keith CT, Borisy AA, Stockwell BR. 2005. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4:71-78. http://dx.doi.org/10.1038/nrd1609.
43. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, Robb ML, Michael NL, Birx DL, McCutchan FE. 2008. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376:101-111. http://dx.doi.org/10.1016/j.virol.2008.03.017.
44. Albin JS, Harris RS. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12:e4. http://dx.doi.org/10.1017/S1462399409001343.
45. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M. 2008. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 15:1059-1066. http://dx.doi.org/10.1038/nsmb.1495.
46. Refsland EW, Hultquist JF, Harris RS. 2012. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8:e1002800. http://dx.doi.org/10.1371/journal.ppat.1002800.
47. Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA deaminase acts processively 3=→5= on single-stranded DNA. Nat. Struct. Mol. Biol. 13:392-399. http://dx.doi.org/10.1038/nsmb1086.
48. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096-7108. http://dx.doi.org/10.1093/nar/gkm750.
49. Iwatani Y, Takeuchi H, Strebel K, Levin JG. 2006. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80:5992-6002. http://dx.doi.org/10.1128/JVI.02680-05.
50. Iwami S, Sato K, De Boer RJ, Aihara K, Miura T, Koyanagi Y. 2012. Identifying viral parameters from in vitro cell cultures. Front. Microbiol. 3:319. http://dx.doi.org/10.3389/fmicb.2012.00319.
51. Iwami S, Holder BP, Beauchemin CA, Morita S, Tada T, Sato K, Igarashi T, Miura T. 2012. Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model. Retrovirology 9:18. http://dx.doi.org/10.1186/1742-4690-9-18.
52. Fukuhara M, Iwami S, Sato K, Nishimura Y, Shimizu H, Aihara K, Koyanagi Y. 2013. Quantification of the dynamics of enterovirus 71 infection by experimental-mathematical investigation. J. Virol. 87:701-705. http://dx.doi.org/10.1128/JVI.01453-12.
53. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
54. Suspene R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. 2005. Recovery of APOBEC3-edited human immunodeficiency virus G→A hypermutants by differential DNA denaturation PCR. J. Gen. Virol. 86:125- 129. http://dx.doi.org/10.1099/vir.0.80426-0.